General Company Information
01. What does Aegerion Pharmaceuticals UK specialize in?
Aegerion Pharmaceuticals UK focuses on developing and commercializing innovative therapies for patients with rare and ultra-rare diseases, particularly in the area of lipid disorders.
02. Is Aegerion Pharmaceuticals UK part of a larger organization?
Yes, Aegerion is part of the Amryt Pharma group, a global biopharmaceutical company dedicated to rare and orphan diseases.
03. Where is Aegerion Pharmaceuticals UK located?
Aegerion Pharmaceuticals UK operates from its offices in the United Kingdom. For specific contact details, please refer to our Contact Us page.
Products and Treatments
01. What medicines does Aegerion Pharmaceuticals UK currently offer?
We market therapies for rare lipid disorders, including lomitapide (brand name: Lojuxta®), used to treat Homozygous Familial Hypercholesterolemia (HoFH).
02. What is Lojuxta® and what is it used for?
Lojuxta® (lomitapide) is indicated as an adjunctive therapy for adult patients with Homozygous Familial Hypercholesterolemia (HoFH), a rare genetic disorder characterized by dangerously high cholesterol levels.
03. How can I access Aegerion’s treatments in the UK?
Our medicines are prescribed by specialist clinicians and are available through the NHS or private healthcare channels. Access may vary depending on individual patient circumstances.
Patients and Support
01. Are there patient support programs available for Aegerion medicines?
Yes, we offer dedicated patient support services to help with treatment access, adherence, and education. Contact your prescribing physician or our support team for details.
02. Where can patients find more information about HoFH and its treatment?
Patients can consult healthcare professionals and also access resources provided through rare disease organizations and Aegerion’s official patient information materials.
03. How can healthcare professionals request medical information or report adverse events?
Healthcare professionals can contact our Medical Information team or use our online reporting form. Adverse events can also be reported via the MHRA’s Yellow Card scheme.
04. Are there educational resources available for clinicians?
Yes, Aegerion offers disease awareness materials, product information, and ongoing education opportunities. Please contact our Medical Affairs department for more information.
Regulatory and Safety
01. Is Lojuxta® approved by UK regulatory authorities?
Yes, Lojuxta® has received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
02. How do I report a side effect or complaint about a product?
Side effects or product complaints should be reported directly to Aegerion’s pharmacovigilance team or via the MHRA Yellow Card reporting system.
03. Are there current job openings at Aegerion Pharmaceuticals UK?
Job openings, when available, are posted on the careers section of our website or on affiliated job boards. We welcome applications from candidates passionate about rare diseases.
04. How can I partner or collaborate with Aegerion Pharmaceuticals UK?
We are open to collaborations with healthcare providers, research institutions, and advocacy groups. Please reach out through our Business Development or Medical Affairs contact form.